Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Revvity Inc.(RVTY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RVTY
09/23/2026: RVTY (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Revvity Inc. is a focused life sciences and diagnostics company that provides essential research tools, laboratory equipment, and clinical testing solutions. The company is known for its strong position in reproductive health and its efforts to integrate digital informatics into scientific workflows. A primary growth opportunity lies in leveraging its specialized diagnostic platforms to serve the evolving needs of personalized medicine. However, the company faces risks from intense competition against larger industry conglomerates and sensitivity to fluctuations in global research spending. The stock may suit investors seeking long-term exposure to healthcare innovation, though success depends heavily on the effective execution of its refined business strategy.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Revvity offers moderate growth potential tied to life science research spending. |
| Momentum investor | Weak fit | Stock performance is currently driven by long-term structural shifts rather than rapid, short-term price momentum. |
| Value investor | Mixed fit | The valuation is often tied to the company's long-term transformation into a specialized diagnostics player. |
| Dividend investor | Mixed fit | Provides consistent income but is not a high-yield dividend play. |
| Low-risk investor | Mixed fit | While established, the company faces industry-specific risks and ongoing integration challenges. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | Biotech and diagnostic sector sentiment can lead to broader market price swings. |
| Valuation risk | Medium | Priced based on future R&D innovation success which carries inherent uncertainty. |
| Competition risk (TMO, DHR) | Medium / high | Competing against firms with significantly larger R&D and distribution budgets. |
| Business quality | Strong | High barrier to entry for diagnostic and scientific instrumentation markets. |
| Dividend income | Low | Dividends are reliable but not the primary reason for holding the stock. |
| Execution risk | Medium | Successful integration of acquired technologies remains critical to long-term performance. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 13.52% | Avg. Invested days 48 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 15.86B USD | Price to earnings Ratio 68.99 | 1Y Target Price 128.47 |
Price to earnings Ratio 68.99 | 1Y Target Price 128.47 | ||
Volume (30-day avg) 1.9M shares | Beta 1.09 | 52 Weeks Range 81.17 - 149.52 | Updated Date 09/23/2026 |
52 Weeks Range 81.17 - 149.52 | Updated Date 09/23/2026 | ||
Dividends yield (FY) 0.20% | Basic EPS (TTM) 2.06 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Life Sciences | Instruments, reagents, and informatics software for pharmaceutical research. | Revenue comes from tools that help scientists discover new drugs faster. |
| Diagnostics | Clinical diagnostic kits and testing services for reproductive health and genomics. | Revenue is driven by clinical testing needs and routine healthcare screenings. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 68.99 | Forward PE 24.39 | Enterprise Value 18.31B | Price to Sales(TTM) 5.45 |
Enterprise Value 18.31B | Price to Sales(TTM) 5.45 | ||
Enterprise Value to Revenue 6.29 | Enterprise Value to EBITDA 23.72 | Shares Outstanding 111.59M | Shares Floating 102.49M |
Shares Outstanding 111.59M | Shares Floating 102.49M | ||
Percent Insiders 0.26 | Percent Institutions 96.55 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Revvity Inc.
Exchange NYSE | Headquarters Waltham, MA, United States | ||
IPO Launch date 1983-04-06 | CEO, President & Director Dr. Prahlad R. Singh Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 11000 | Website https://www.revvity.com |
Full time employees 11000 | Website https://www.revvity.com | ||
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.